Show simple item record

dc.contributor.authorvan Wamel, A
dc.contributor.authorSontum, PC
dc.contributor.authorHealey, A
dc.contributor.authorKvåle, S
dc.contributor.authorBush, N
dc.contributor.authorBamber, J
dc.contributor.authorde Lange Davies, C
dc.date.accessioned2017-04-03T10:14:39Z
dc.date.issued2016-08
dc.identifier.citationJournal of controlled release : official journal of the Controlled Release Society, 2016, 236 pp. 15 - 21
dc.identifier.issn0168-3659
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/550
dc.identifier.eissn1873-4995
dc.identifier.doi10.1016/j.jconrel.2016.06.018
dc.description.abstractAcoustic cluster therapy (ACT) is a novel approach for ultrasound mediated, targeted drug delivery. In the current study, we have investigated ACT in combination with paclitaxel and Abraxane® for treatment of a subcutaneous human prostate adenocarcinoma (PC3) in mice. In combination with paclitaxel (12mg/kg given i.p.), ACT induced a strong increase in therapeutic efficacy; 120days after study start, 42% of the animals were in stable, complete remission vs. 0% for the paclitaxel only group and the median survival was increased by 86%. In combination with Abraxane® (12mg paclitaxel/kg given i.v.), ACT induced a strong increase in the therapeutic efficacy; 60days after study start 100% of the animals were in stable, remission vs. 0% for the Abraxane® only group, 120days after study start 67% of the animals were in stable, complete remission vs. 0% for the Abraxane® only group. For the ACT+Abraxane group 100% of the animals were alive after 120days vs. 0% for the Abraxane® only group. Proof of concept for Acoustic Cluster Therapy has been demonstrated; ACT markedly increases the therapeutic efficacy of both paclitaxel and Abraxane® for treatment of human prostate adenocarcinoma in mice.
dc.formatPrint-Electronic
dc.format.extent15 - 21
dc.languageeng
dc.language.isoeng
dc.rights.urihttps://www.rioxx.net/licenses/all-rights-reserved
dc.subjectCell Line, Tumor
dc.subjectAnimals
dc.subjectHumans
dc.subjectMice
dc.subjectProstatic Neoplasms
dc.subjectPaclitaxel
dc.subjectAntineoplastic Combined Chemotherapy Protocols
dc.subjectDrug Delivery Systems
dc.subjectMale
dc.subjectDrug Liberation
dc.subjectUltrasonic Waves
dc.subjectAlbumin-Bound Paclitaxel
dc.titleAcoustic Cluster Therapy (ACT) enhances the therapeutic efficacy of paclitaxel and Abraxane® for treatment of human prostate adenocarcinoma in mice.
dc.typeJournal Article
dcterms.dateAccepted2016-06-09
rioxxterms.versionofrecord10.1016/j.jconrel.2016.06.018
rioxxterms.licenseref.urihttps://www.rioxx.net/licenses/all-rights-reserved
rioxxterms.licenseref.startdate2016-08
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfJournal of controlled release : official journal of the Controlled Release Society
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Ultrasound & Optical Imaging
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Ultrasound & Optical Imaging
pubs.publication-statusPublished
pubs.volume236
pubs.embargo.termsNot known
icr.researchteamUltrasound & Optical Imagingen_US
dc.contributor.icrauthorBamber, Jeffreyen


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record